REVENUE (Tables)

3 Months Ended

Jun. 30, 2022

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the six months ended June 30, 2022, is as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2021	$	21.5	$	13.9	$	0.7	$	36.1
Plus, credit loss expense	3.0		—		—		3.0
Less, write offs	(3.2)		(2.5)		—		(5.7)
Balance as of June 30, 2022	$	21.3	$	11.4	$	0.7	$	33.4

Contract with Customer, Asset and Liability [Table Text Block]

	June 30, 2022		December 31, 2021
Dx accounts receivable	$	1,066.4	$	1,193.8
DD accounts receivable	1,171.3		1,089.2
Less DD allowance for doubtful accounts	(21.3)		(21.5)
Accounts receivable	$	2,216.4	$	2,261.5
Gross unbilled services	$	838.8	$	730.8
Less reserve for unbilled services	(11.4)		(14.0)
Unbilled services	$	827.4	$	716.8
Unearned revenue	$	544.2	$	558.5

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2022, and 2021, were as follows:

	For the Three Months Ended June 30, 2022								For the Three Months Ended June 30, 2021
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	18	%	—	%	—	%	18	%	17	%	—	%	—	%	17	%
Patients	7	%	—	%	—	%	7	%	7	%	—	%	—	%	7	%
Medicare and Medicaid	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Third party	30	%	—	%	—	%	30	%	31	%	—	%	—	%	31	%
Total Dx revenues by payer	61	%	—	%	—	%	61	%	61	%	—	%	—	%	61	%
DD
Pharmaceutical, biotechnology and medical device companies	19	%	13	%	7	%	39	%	23	%	12	%	4	%	39	%
Total revenues	80	%	13	%	7	%	100	%	84	%	12	%	4	%	100	%

	For the Six Months Ended June 30, 2022								For the Six Months Ended June 30, 2021
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	17	%	—	%	—	%	17	%	18	%	—	%	—	%	18	%
Patients	7	%	—	%	—	%	7	%	6	%	—	%	—	%	6	%
Medicare and Medicaid	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Third party	32	%	—	%	—	%	32	%	33	%	—	%	—	%	33	%
Total Dx revenues by payer	62	%	—	%	—	%	62	%	63	%	—	%	—	%	63	%
DD
Pharmaceutical, biotechnology and medical device companies	18	%	13	%	7	%	38	%	22	%	11	%	4	%	37	%
Total revenues	80	%	13	%	7	%	100	%	85	%	11	%	4	%	100	%

Revenues in the U.S. were $2,856.9 (77.3%) and $3,091.3 (80.5%) for the three months ended June 30, 2022, and 2021, respectively, and for the six months ended June 30, 2022, and 2021, were $5,857.5 (77.1%) and $6,537.4 (81.7%), respectively.

DD Contract costs

Capitalized Contract Cost [Table Text Block]

	June 30, 2022		December 31, 2021
Sales commission assets	$	40.2	$	36.2
Deferred contract fulfillment costs	15.0		14.4
Total	$	55.2	$	50.6